- Home
- GNS vs PRLD Comparison
GNS vs PRLD Comparison
Compare GNS & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNS
- PRLD
- Stock Information
- Founded
- GNS 2002
- PRLD 2016
- Country
- GNS Singapore
- PRLD United States
- Employees
- GNS N/A
- PRLD N/A
- Industry
- GNS Other Consumer Services
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- GNS Real Estate
- PRLD Health Care
- Exchange
- GNS Nasdaq
- PRLD Nasdaq
- Market Cap
- GNS 81.8M
- PRLD 69.1M
- IPO Year
- GNS 2022
- PRLD 2020
- Fundamental
- Price
- GNS $0.88
- PRLD $1.38
- Analyst Decision
- GNS
- PRLD Strong Buy
- Analyst Count
- GNS 0
- PRLD 3
- Target Price
- GNS N/A
- PRLD $4.00
- AVG Volume (30 Days)
- GNS 1.1M
- PRLD 3.4M
- Earning Date
- GNS 09-23-2025
- PRLD 10-31-2025
- Dividend Yield
- GNS N/A
- PRLD N/A
- EPS Growth
- GNS N/A
- PRLD N/A
- EPS
- GNS N/A
- PRLD N/A
- Revenue
- GNS $5,749,894.00
- PRLD $7,000,000.00
- Revenue This Year
- GNS $82.78
- PRLD N/A
- Revenue Next Year
- GNS $85.90
- PRLD N/A
- P/E Ratio
- GNS N/A
- PRLD N/A
- Revenue Growth
- GNS N/A
- PRLD N/A
- 52 Week Low
- GNS $0.21
- PRLD $0.61
- 52 Week High
- GNS $1.92
- PRLD $4.22
- Technical
- Relative Strength Index (RSI)
- GNS 55.59
- PRLD 47.91
- Support Level
- GNS $0.69
- PRLD $1.17
- Resistance Level
- GNS $0.78
- PRLD $4.19
- Average True Range (ATR)
- GNS 0.06
- PRLD 0.37
- MACD
- GNS 0.01
- PRLD -0.08
- Stochastic Oscillator
- GNS 82.84
- PRLD 6.20
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education, which involves entrepreneur education, management consultancy, and business development tools; and Campus, consisting of resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America. The company derives maximum revenue from Europe/Middle East/Africa.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.